---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-011205"
form_type: "8-K"
ticker: "TARA"
cik: "0001359931"
company_name: "Protara Therapeutics, Inc."
filed_at: "2022-03-09T23:59:59+00:00"
generated_at: "2026-06-27T00:19:46.884585+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Protara Therapeutics reports Q4 net loss of $10.2M; cash $130.7M funds operations into mid-2024

## Summary
- Net loss for Q4 2021 was $10.2M ($0.91 loss per share); full year net loss $47.3M ($4.21 loss per share).
- Cash and marketable securities $130.7M as of Dec 31, 2021; expected to fund operations into mid-2024.
- R&D expenses rose to $4.1M in Q4 (vs $3.7M prior year) and $21.1M for full year (vs $12.0M).
- Phase 1 trial of TARA-002 in non-muscle invasive bladder cancer (NMIBC) has commenced after FDA IND clearance.
- Jathin Bandari, M.D., appointed as Chief Medical Officer in January 2022; previously Interim CMO.

## SEC filing metadata
- accession: 0001213900-22-011205
- form_type: 8-K
- ticker: TARA
- cik: 0001359931
- company_name: Protara Therapeutics, Inc.
- filed_at: 2022-03-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1359931/000121390022011205/0001213900-22-011205-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1359931/000121390022011205/ea156484-8k_protara.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-011205
- JSON: https://secwatch.observer/filing/0001213900-22-011205.json
- Plain text: https://secwatch.observer/filing/0001213900-22-011205.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.